Ten facts about the format.
The detail behind what we showed you.
You have the story. This is the layer underneath it: the numbers, the specifications, and the studies. Nothing here is a new argument for why the format matters. It is the evidence for what you already heard.
HOW IT GOES IN
01
It disperses in the mouth in about a second and a half.
No pill to hide in food, no paste to fight over, and no question afterward about whether the dose went down. This improves compliance, especially for courses of treatment that last for several days or medications given daily for chronic conditions, situations where treatment plans frequently fail.
02
It absorbs across the mucosa, so it skips digestion entirely.
The drug crosses the lining of the cheek directly into the bloodstream. It does not have to survive the stomach, because it is absorbed before digestion starts.
03
It is stable in your hand and gone in their mouth.
The tablet handles, packages, and ships without special conditions. It is engineered to disperse the moment it meets saliva, not from being held, dropped, or left on a counter.
WHAT IT DOES TO THE MOLECULE
04
It is freeze-dried, not compressed.
The speed is not a coating or an additive. Freeze-drying leaves a high-porosity matrix: an open structure that takes on saliva the moment it makes contact. The tablet is mostly structured empty space, which makes the speed a manufacturing outcome rather than a formulation trick.
05
It carries up to 400 mg insoluble or 60 mg soluble of active ingredients.
This is the number most often used to rule the format out, and it is usually used wrong. For APIs in which the salt or excipient contributes greatly to the dose, it is possible to use an alternative form, which typically means meaningfully less active drug is needed to reach the same target. Before you disqualify a compound, talk with us.
06
It takes roughly 20 to 60 percent less active drug per dose to reach the same target.
The mucosal route bypasses first-pass metabolism through the liver, which can eliminate up to 80 percent of an orally delivered dose. That is the biggest reason less active drug is needed to reach the same target. Fewer excipients at a lower drug load also means less material to account for in the safety margin.
07
Tablets are shelf stable for up to three years.
No special storage conditions and no cold chain.
WHETHER IT IS REAL
08
The platform has more than thirty years in human medicine.
More than 35 approved human products across pain, allergy, and nausea. More than 20 issued patents across more than 60 countries. Roughly 1.2 billion tablets a year. ODT holds seven animal-health-specific patents on top of it.
09
Seven Therapeutic Categories. Four species. In vivo, with the curves to show for it.
Drugs from each of the following categories have all been through the platform and into animals across horses, cattle, dogs, and cats.
• Beta-Agonist
• Proton Pump Inhibitor
• Parasiticide
• NSAID
• Tranquilizer
• Sedative
• Antibiotic
10
The lead program runs through an existing NADA, on an established line.
Not a novel regulatory pathway. Production runs on dedicated freeze-drying equipment at the Catalent facility in Swindon, England, which is FDA inspected and EMA approved, and ODT retains manufacturing rights across the platform.
Fact 1 is the reason the company exists. The other nine are why it holds up.
Prepared for the companies we are meeting with. September 2026. Not for public distribution.